These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38615930)

  • 1. PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma.
    Liang JH; Wang WT; Wang R; Gao R; Du KX; Duan ZW; Zhang XY; Li Y; Wu JZ; Yin H; Shen HR; Wang L; Li JY; Guo JR; Xu W
    Cancer Lett; 2024 Jun; 591():216877. PubMed ID: 38615930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
    Liu L; Yan H; Ruan M; Yang H; Wang L; Lei B; Sun X; Chang C; Huang G; Xie W
    Cancer Sci; 2021 Aug; 112(8):3083-3098. PubMed ID: 34033176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
    BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
    Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R
    Blood Adv; 2024 Jan; 8(1):150-163. PubMed ID: 37782774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
    Brown-Burke F; Hwang I; Sloan S; Hinterschied C; Helmig-Mason J; Long M; Chan WK; Prouty A; Chung JH; Zhang Y; Singh S; Youssef Y; Bhagwat N; Chen Z; Chen-Kiang S; Di Liberto M; Elemento O; Sehgal L; Alinari L; Vaddi K; Scherle P; Lapalombella R; Paik J; Baiocchi RA
    Blood Adv; 2023 Oct; 7(20):6211-6224. PubMed ID: 37327122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
    Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
    J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
    Karkhanis V; Alinari L; Ozer HG; Chung J; Zhang X; Sif S; Baiocchi RA
    J Biol Chem; 2020 Jan; 295(5):1165-1180. PubMed ID: 31822509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
    Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
    Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.
    Chen J; Ding C; Chen Y; Hu W; Yu C; Peng C; Feng X; Cheng Q; Wu W; Lu Y; Xie H; Zhou L; Wu J; Zheng S
    Cancer Lett; 2021 Apr; 502():154-165. PubMed ID: 33340617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
    Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
    Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
    Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW
    Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRMT5 confers lipid metabolism reprogramming, tumour growth and metastasis depending on the SIRT7-mediated desuccinylation of PRMT5 K387 in tumours.
    Yuan HF; Zhao M; Zhao LN; Yun HL; Yang G; Geng Y; Wang YF; Zheng W; Yuan Y; Song TQ; Niu JQ; Zhang XD
    Acta Pharmacol Sin; 2022 Sep; 43(9):2373-2385. PubMed ID: 35046516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
    Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
    Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma.
    Zhang X; Wu J; Wu C; Chen W; Lin R; Zhou Y; Huang X
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):337-342. PubMed ID: 30446222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer.
    Chakraborty PK; Xiong X; Mustafi SB; Saha S; Dhanasekaran D; Mandal NA; McMeekin S; Bhattacharya R; Mukherjee P
    Oncotarget; 2015 Nov; 6(35):37367-84. PubMed ID: 26452259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.
    Li X; Chen YT; Josson S; Mukhopadhyay NK; Kim J; Freeman MR; Huang WC
    PLoS One; 2013; 8(8):e70987. PubMed ID: 23951060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
    Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SREBP1/FASN/cholesterol axis facilitates radioresistance in colorectal cancer.
    Jin Y; Chen Z; Dong J; Wang B; Fan S; Yang X; Cui M
    FEBS Open Bio; 2021 May; 11(5):1343-1352. PubMed ID: 33665967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-κB pathway.
    Zhang L; Shao G; Shao J; Zhao J
    Tissue Cell; 2022 Jun; 76():101788. PubMed ID: 35339800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
    Pal S; Baiocchi RA; Byrd JC; Grever MR; Jacob ST; Sif S
    EMBO J; 2007 Aug; 26(15):3558-69. PubMed ID: 17627275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.